Clinical Trial Update: Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 START trial evaluating the combination of selinexor and talazoparib in advanced refractory solid tumors and triple-negative breast cancer is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Talzenna (talazoparib)
• XPOVIO (selinexor)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers | Phase 1, Phase 2 | Status: RECRUITING